CONFERENCE COVERAGE SERIES
Center for Neurogenerative Disease Research Retreat 2001
Philadelphia, Pennsylvania
07 November 2001
CNDR 2nd Annual Retreat: Welcome and Introduction
The Center for Neurodegenerative Disease Research (CNDR) at the University of Pennsylvania School of Medicine organized the 2nd Annual CNDR Retreat as a one day symposium entitled "Emerging Alzheimer's Disease Therapies...
CNDR 2nd Annual Retreat: Amyloid-binding Ligands as AD Therapies
Virginia M.-Y. Lee, University of Pennsylvania School of Medicine, summarized studies conducted by investigators in CNDR in collaboration with the Kung lAβ at Penn that seek to identify new therapies for AD...
CNDR 2nd Annual Retreat: Gonadal Hormones Control β-Amyloid in Vivo
Dr. Samuel Gandy of Thomas Jefferson Medical School began his presentation by stating that since 1990, 14 of 15 epidemiological studies reported that hormone replacement therapy (HRT) reduced the relative risk of AD in postmenopausal women by about 50 percent...
CNDR 2nd Annual Retreat: Metal Complexing Agents as Therapies for AD
According to Ashley Bush of Harvard Medical School, Aβ is rapidly precipitated by Zn2+ at low physiological concentrations, and Cu2+ and Fe3+ also induce Aβ aggregation...
CNDR 2nd Annual Retreat: Modification of Soluble Aβ Derivatives
Due to the illness of Blas Frangione, New York University School of Medicine, his colleague, E. M. Sigurdsson, gave this presentation on another alternative for immunotherapy of AD. Dr. Sigurdsson reviewed recent studies of transgenic mice with AD-like brain amyloidosis...
CNDR 2nd Annual Retreat: Systemic Immunotherapy for Alzheimer's Disease
Ivan Lieberburg of Elan Corporation summarized evidence over the past 15 years supporting the role of amyloid as causal in the onset and/or progression of AD. Aβ, a 42 amino acid long peptide...
CNDR 2nd Annual Retreat: β-Secretase Inhibitor Therapy for AD
Dr. Citron began his presentation by emphasizing that the cerebral deposition of Aβ is an early and critical feature of AD, and that Aβ is released from APP by the sequential action of two proteases, β-secretase and γ-secretase...
CNDR 2nd Annual Retreat: γ-Secretase: Implications for AD Therapy
Yue-Ming Li, Merck and Company, began his presentation by reviewing the known biology of γ-secretase, a membrane-bound protease that cleaves within the transmembrane region of APP...
CNDR 2nd Annual Retreat: Summary and Conclusions
Dr. Sangram Sisodia provided a summary and critique of the foregoing scientific presentations wherein he outlined the strengths and weaknesses of each of the approaches discussed at the symposium...